Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy

被引：47

作者：

Castelo-Branco, Camil

Nomdedeu, Benet

Camus, Adela

Mercadal, Santiago

Martinez de Osaba, Maria Jesus

Balasch, Juan

机构：

[1] Univ Barcelona, Hosp Clin Barcelona, Fac Med, Inst Clin Ginecol Obstet & Neonatol, E-08036 Barcelona, Spain

[2] Hosp Clin, Clin Inst Hematol & Oncol, Santiago, Spain

[3] Clin Las Condes, Dept Obstet & Ginecol, Unidad Med Reprod, Santiago, Spain

[4] Hosp Clin Barcelona, Ctr Diagnost Biomed, Barcelona, Spain

[5] IDIBAPS, Barcelona, Spain

来源：

FERTILITY AND STERILITY | 2007年 / 87卷 / 03期

关键词：

D O I：

10.1016/j.fertnstert.2006.10.004

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In young women receiving chemotherapy for Hodgkin's disease, the combined use of triptorelin and tibolone cotreatment may be a useful tool for preserving ovarian function because all but three (10%) of the women in this treatment group returned to spontaneous ovulation and menses, in contrast to 23% of subjects in the control group (P <.05). No significant differences were observed in bone mineral density between groups.

引用

页码：703 / 706

页数：4

共 27 条

[1] Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women [J].